T. Rowe Price Associates
TENX icon

T. Rowe Price Associates’s Tenax Therapeutics TENX Stock Holding History

T. Rowe Price Associates’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.84M Sell
607,660
-2,343,456
-79% -$29.9M ﹤0.01% 1366
2026
Q1 		$47.2M Buy
+2,951,116
New +$39.9M 0.01% 787
2024
Q4 		– Sell
-24,000
Closed -$84K – 3057
2024
Q3 		$84K Buy
+24,000
New +$86.9K ﹤0.01% 2853

Other funds holding TENX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Associates's TENX Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Tenax Therapeutics (TENX) stake by 79% in Q2 2026, selling an estimated $29.9M and leaving 607,660 shares worth $8.84M. The position accounts for ﹤0.01% of the portfolio, ranked #1366.

T. Rowe Price Associates first reported a position in TENX in Q3 2024 and has held it in 3 quarters since. The position peaked at $47.2M in Q1 2026. 111 funds tracked by Wall St. Rank hold TENX as of Q2 2026.

  • T. Rowe Price Associates held 607,660 shares of Tenax Therapeutics worth $8.84M as of Q2 2026.
  • T. Rowe Price Associates sold 2,343,456 Tenax Therapeutics shares in Q2 2026, an estimated $29.9M.
  • Tenax Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1366 holding.
  • T. Rowe Price Associates first reported a position in Tenax Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • T. Rowe Price Associates's Tenax Therapeutics position peaked at $47.2M in Q1 2026.
  • 111 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.